Accessibility Menu
Tao Synergies logo

Tao Synergies(NASDAQ) TAOX

Current Price$3.58
Market Cap$27.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-96%
5 Year-99%
1 Year-59%
1 Month+1%
Tao Synergies last closing stock price
MetricPriceDate
Last closeUSD 3.672026-07-22
Tao Synergies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.18%USD 3.832026-07-15
1 month+1.1%USD 3.632026-06-22
3 month-28.6%USD 5.142026-04-23
Year to date-0.27%USD 3.682025-12-31
1 year-58.81%USD 8.912025-07-22
3 year-82.93%USD 21.502023-07-21
5 year-98.79%USD 302.502021-07-23
Since inception-95.73%USD 86.002020-12-08

Tao Synergies Financials at a Glance

Market Cap

$27.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$687.84K

Net Income (TTM)

-$24.87M

EPS (TTM)

-$13.42

P/E Ratio

-0.27

Dividend

$0.00

Beta (Volatility)

1.50 (Average)

Price

$3.58

Volume

0

Open

$3.86

Previous Close

$3.58

Daily Range

$3.58 - $3.86

52-Week Range

$3.22 - $10.00

Estimated Earnings Date

Jun 3, 2026

TAOX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tao Synergies

TAO Synergies develops treatments for brain diseases and manages digital assets. Its main drug targets Alzheimer’s, while its crypto strategy generates income. The company serves patients, researchers, and digital asset investors.

Products and Services

  • Biopharmaceutical R&D: Develops bryostatin-1 for Alzheimer’s and other brain disorders (0% of 2025 revenue).
  • Digital Asset Treasury: Acquires and stakes TAO cryptocurrency for yield (100% of 2025 revenue).
  • Media Platform: Operates The TAO Daily, providing news on the Bittensor crypto ecosystem.
  • Consulting Services: Engages advisors for crypto portfolio management and strategic planning.

Growth and Expansion

  • Launched digital asset treasury strategy in June 2025, focusing on TAO cryptocurrency.
  • Formed TAOX Florida Inc. in 2025 for crypto operations.
  • Launched The TAO Daily media platform in September 2025.
  • Engaged consultants like James Altucher and Joseph Jacks for crypto strategy in 2025.
  • Entered staking agreements with BitGo and Yuma in 2025.

What Makes TAO Synergies Stand Out

The company shifted from drug development to a concentrated crypto treasury model. It holds exclusive licenses for bryostatin technology and operates a media platform for the Bittensor ecosystem. All digital assets are staked for yield, with no diversification beyond TAO.

Five Things You Need to Know

  • Revenue was $299,061 in 2025, up from $0 in 2024 (+100%).
  • Net loss was $28.7 million in 2025, up 125.1% from 2024.
  • Digital assets reached $17.9 million at year-end 2025, up from $0 in 2024.
  • General and administrative expenses rose 73.1% to $9.0 million in 2025.
  • Cash fell to $5.5 million at year-end 2025, down from $17.7 million in 2024.

Bottom Line

TAO Synergies evolved from drug research to a focused crypto asset strategy. Its business now centers on staking TAO for income and managing digital asset risks.

AI Generated • Apr 16, 2026

Industry

Software

Sector

Information Technology

Employees

5

CEO

Alan J. Tuchman, MD, MBA

Website

www.synaptogen.com

Headquarters

New York, NY 10036, US

TAOX Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-1453.20%

Net Income Margin

-3615.43%

Return on Equity

-120.29%

Return on Capital

-41.31%

Return on Assets

-80.10%

Earnings Yield

-3.70%

Dividend Yield

0.00%

Payout Ratio

-1.30%

Stock Overview

Market Cap

$27.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

7.47M

Volume

0

Avg. Volume

125.80K

Financials (TTM)

Gross Profit

$687.84K

Operating Income

-$10.00M

EBITDA

-$9.29M

Operating Cash Flow

-$6.08M

Capital Expenditure

-$4.00

Free Cash Flow

-$6.08M

Cash & ST Invst.

$28.80M

Total Debt

$0.00

Tao Synergies Performance Analysis

Tao Synergies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 299,061N/A
Tao Synergies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-305033.0%
Q42025-12-31-54.9%
Q12026-03-31323.8%
Tao Synergies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -20.35-67.6%
20232023-12-31USD -29.5645.3%
20242024-12-31USD -10.99-62.8%
20252025-12-31USD -8.81-19.8%
Tao Synergies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-9483.3%
Q32025-09-3086.1%
Q42025-12-3133.3%
Q12026-03-31141.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$388.77K

N/A

Gross Profit

$388.77K

N/A

Gross Margin

100.00%

N/A

Market Cap

$27.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$6.86M

N/A

Employees

4

N/A

Net Income

$4.25M

+1004.6%

EBITDA

-$1.32M

-23.3%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$28.80M

+94.2%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-80.10%

N/A

Return on Invested Capital

-33.38%

N/A

Free Cash Flow

-$1.68M

+15.9%

Operating Cash Flow

-$1.68M

+15.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IBIOiBio, Inc.
$1.38-2.13%
KLTOKlotho Neurosciences, Inc.
$0.38-7.10%
NXTCNextCure, Inc.
$4.40-13.89%
PSTVPlus Therapeutics, Inc.
$3.82-2.55%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$10.96-0.02%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$70.28-0.02%

Questions About TAOX

What is the current price of Tao Synergies?

Tao Synergies is trading at $3.58 per share.

What is the 52-week range for Tao Synergies?

Over the past 52 weeks, Tao Synergies has traded between $3.22 and $10.00.

How much debt does Tao Synergies have?

As of the most recent reporting period, Tao Synergies reported total debt of $0.00.

How much cash does Tao Synergies have on hand?

Tao Synergies reported $3.65M in cash and cash equivalents in its most recent financial results.

What is Tao Synergies’s dividend yield?

Tao Synergies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services